Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings

SAN DIEGO – Nov. 10, 2016Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced updated data from the company’s clinical and preclinical studies of Toca 511 and Toca FC in high grade glioma will be highlighted in oral and poster presentations at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), the 2nd CNS Anticancer Drug Discovery And Development Conference and the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting.

Data to be presented at SNO


Oral Presentation:

Complementary clinical and ancillary data from 123 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial.

Presenter: Manish Aghi, M.D., Ph.D., associate professor of neurological surgery at University of California, San Francisco
Date and Time: Friday, Nov. 18, 3:35-3:40 p.m. MT

Poster Presentations:

Toca 511 and 5-fluorocytosine with checkpoint inhibitors reduced tumor burden in a mouse model of glioma

Presenter: Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT

Investigation of anti-tumor cellular immune response elicited by Toca 511 & Toca FC therapy in a recurrent HGG phase 1 trial

Presenter: Derek Ostertag, Ph.D., department leader of R&D diagnostics at Tocagen
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT

Systematic identification of Toca 511 retrovirus integration sites and mutation profiles in tumor and blood samples from patients undergoing investigational treatment for recurrent high grade glioma correlates with favorable clinical safety profile

Presenter: Daniel Hogan, Ph.D., bioinformatics scientist at Tocagen
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT

Successful cancer-selective gene delivery following intravenous Toca 511 delivery in patients with recurrent high grade glioma (HGG)

Presenter: Jolene Shorr, senior director, clinical science at Tocagen
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT

The Toca 7 Study:  Phase 1b Study of Toca 511, a live gamma retrovirus, and Toca FC, an extended-release formulation of 5-fluorocytosine Combined with Standard of Care in Newly Diagnosed High Grade Glioma (NCT02598011)

Presenter: Tiffany Huang, Ph.D., medical science liaison at Tocagen
Date and Time: Friday, Nov. 18, 7:30-9:30 p.m. MT

Data to be presented at the CNS Anticancer Drug Discovery and Development Conference:


Oral presentations:

Successful cancer-selective gene delivery following intravenous Toca 511 delivery in patients with recurrent high grade glioma (HGG)

Presenter: Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program
Date and Time: Thursday, Nov. 17, 9:07-9:19 a.m. MT

Toca 511 and 5-fluorocytosine with checkpoint inhibitors reduced tumor burden in a mouse model of glioma

Presenter: Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen
Date and Time: Thursday, Nov. 17, 12:15-12:27 p.m. MT

Data to be presented at SITC:


Poster Presentation:

Gene transfer of cytosine deaminase with Toca 511 and subsequent treatment with 5-fluorocytosine induces anti-tumor immunity

Presenter: Leah Mitchell, Ph.D., research scientist at Tocagen
Date and Time: Friday, Nov. 11, 12:15-1:30 p.m. and 6:15-7:30 p.m. ET

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. The company is developing its lead investigational product candidate, Toca 511 (vocimagene amiretrorepvec) & Toca FC (extended-release 5-fluorocytosine), initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Tocagen has initiated the Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC in patients with recurrent HGG, which is designed to serve as a potential registrational trial. More information about the clinical trial can be found at www.tocagen.com/toca5. Tocagen has initiated a clinical trial of Toca 511 & Toca FC in metastatic cancers, including colorectal, pancreatic, lung, breast, renal and melanoma. Tocagen obtained Fast Track designation from the U.S. Food and Drug Administration for Toca 511 & Toca FC as a treatment of recurrent HGG and Orphan drug designation for the treatment of glioblastoma multiforme (GBM), a subset of HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.

###

 

Media Contact:
Monica May
Canale Communications
(619) 849-5383
monica@canalecomm.com